ARTA
TCRT icon

A.R.T. Advisors’s Alaunos Therapeutics TCRT Stock Holding History

A.R.T. Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-122
Closed -$86K – 892
2019
Q4 		$86K Sell
122
-630
-84% -$434K ﹤0.01% 1224
2019
Q3 		$483K Buy
752
+640
+571% +$508K 0.02% 877
2019
Q2 		$98K Buy
+112
New +$77K 0.01% 1198
2017
Q4 		– Sell
-441
Closed -$406K – 1662
2017
Q3 		$406K Sell
441
-2,303
-84% -$2.05M 0.02% 896
2017
Q2 		$2.56M Buy
2,744
+2,008
+273% +$1.97M 0.14% 205
2017
Q1 		$699K Buy
+736
New +$685K 0.03% 683
2016
Q3 		– Sell
-962
Closed -$792K – 1132
2016
Q2 		$792K Sell
962
-594
-38% -$647K 0.04% 634
2016
Q1 		$1.73M Buy
+1,556
New +$1.59M 0.08% 379
2015
Q2 		– Sell
-4,334
Closed -$7M – 1711
2015
Q1 		$7M Buy
+4,334
New +$6.42M 0.24% 98
2014
Q4 		– Sell
-773
Closed -$306K – 1643
2014
Q3 		$306K Buy
773
+23
+3% +$11.1K 0.01% 930
2014
Q2 		$453K Buy
750
+139
+23% +$77.4K 0.02% 819
2014
Q1 		$419K Buy
+611
New +$409K 0.02% 836

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

A.R.T. Advisors's TCRT Position: Q1 2020 in Review

A.R.T. Advisors sold out of Alaunos Therapeutics (TCRT) in Q1 2020, closing a stake of 122 shares — an estimated $86K sold.

A.R.T. Advisors first reported a position in TCRT in Q1 2014 and held it in 12 quarters. The position peaked at $7M in Q1 2015. 146 funds tracked by Wall St. Rank hold TCRT as of Q1 2020.

  • A.R.T. Advisors reported no remaining Alaunos Therapeutics position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 122 Alaunos Therapeutics shares in Q1 2020, an estimated $86K.
  • A.R.T. Advisors first reported a position in Alaunos Therapeutics in Q1 2014 and held it in 12 quarters.
  • A.R.T. Advisors's Alaunos Therapeutics position peaked at $7M in Q1 2015.
  • 146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.